PATIENT OUTCOMES WITH ANTIBIOTIC THERAPY OF LYME DISEASE
莱姆病抗生素治疗的患者结局
基本信息
- 批准号:3373165
- 负责人:
- 金额:$ 15.46万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1993
- 资助国家:美国
- 起止时间:1993-03-01 至 1998-02-28
- 项目状态:已结题
- 来源:
- 关键词:Borrelia Lyme disease antibiotics arthritis communicable disease control computer assisted patient care computer program /software disease /disorder classification disease /disorder prevention /control disease /disorder proneness /risk dosage drug administration rate /duration drug administration routes drug adverse effect education evaluation /planning erythema human subject human therapy evaluation interview longitudinal human study medical complication microorganism disease chemotherapy nursing intervention patient care management prognosis syndrome therapy compliance training
项目摘要
Lyme borreliosis (LB), the 2nd most important emerging disease and most
common vector-borne disease in the USA, is caused by infection with the
spirochete, Borrelia burgdorferi. In Maryland, LB is spreading rapidly
and increasing in incidence with reported cases doubling each year.
Infection causes a characteristic rash and "flu-like" symptoms and
chronic and recurrent arthritis, carditis and neurological abnormalities.
LB is difficult to diagnose and it's treatment, particularly therapy of
the chronic stages, remains uncertain and controversial. This project
proposes to improve the quality of care in patients with LB by
investigating differences in patient outcomes resulting from variations
in antibiotic therapy. Inappropriate practice patterns will be
identified and educational interventions to improve treatment practices
will be evaluated.
Using telephone interviews with reporting physicians and all LB cases
reported to the Maryland Department of Health from 1993-1997, we will
obtain information on antibiotics prescribed, patient compliance and
adverse reactions to the drugs and clinical responses to different
regimens for treating erythema migrans (EM), Lyme arthritis and other LB
syndromes. Outcomes to be measured are: improvement or cure of illness
and prevention of complications. The variables are patient-, disease-
(e.g., confirmed or unconfirmed cases, stage of disease, disease
syndrome) and treatment- related (e.g., drug, drug group, dose, length
and route of therapy). During the first 3 years an estimated 1,200 to
1,600 cases of LB will be admitted to the study and followed for 3 years.
In addition to simple contingency table analysis, multiple linear and
logistic regression will be employed to hold the effects of confounders
constant while computing risks and relative risks.
During the 4th and 5th years two physician training interventions will be
evaluated: the area-wide intervention will compare outputs from
physicians practicing in part of the state who receive frequent mailings,
lectures and provision of a LB "hotline" with those practicing in another
area not having these. training exposures. In addition, a randomized
study will compare the effects of a single intervention on half of the
800-to-1,000 physicians reporting LB cases during the first 3 years with
the remaining 400-to-500. Effects of both interventions will be assessed
by observations on clinical practice patterns and by pre- and
termination-testing in the randomized study. Finally, algorithms will be
constructed to assist Maryland physicians managing patients with
suspected LB.
莱姆病(LB),第二个最重要的新兴疾病和最
在美国常见的媒介传播疾病,是由感染
螺旋体,伯氏疏螺旋体。 在马里兰州,LB正在迅速蔓延
发病率逐年上升,报告病例每年翻一番。
感染会引起典型的皮疹和“流感样”症状,
慢性和复发性关节炎、心脏炎和神经系统异常。
LB的诊断和治疗都很困难,尤其是对
慢性阶段,仍然不确定和有争议。 这个项目
建议通过以下措施提高LB患者的护理质量:
研究变异导致的患者结局差异
抗生素治疗。 不适当的实践模式将是
确定和教育干预措施,以改善治疗做法
将被评估。
通过电话采访报告医生和所有LB病例
从1993年到1997年向马里兰州卫生部报告,我们将
获取有关抗生素处方、患者依从性和
药物的不良反应和不同药物的临床反应
用于治疗游走性红斑(EM)、莱姆关节炎和其它LB的方案
综合征 要衡量的结果是:疾病的改善或治愈
预防并发症。 变量是病人,疾病-
(e.g.,确诊或未确诊病例、疾病阶段、疾病
综合征)和治疗相关的(例如,药物、药物组、剂量、长度
和治疗途径)。 在头三年,估计有1,200至
1,600例LB病例将被纳入研究并随访3年。
除了简单的列联表分析外,
将采用逻辑回归来保持混杂因素的影响
在计算风险和相对风险时保持不变。
在第4年和第5年,将进行两次医师培训干预,
评价:全地区干预措施将比较
在该州部分地区执业的医生经常收到邮件,
讲座并提供LB“热线”,与在另一个国家执业的人联系
地区没有这些。培训曝光 此外,随机
这项研究将比较单一干预措施对一半人的影响。
800-1,000名医生在头3年报告了LB病例,
剩下的400到500人 将评估两种干预措施的效果
通过对临床实践模式的观察,
随机化研究中的终止试验。 最后,算法将
构建以协助马里兰州医生管理患者,
怀疑LB
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
George Thomas Strickland其他文献
George Thomas Strickland的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('George Thomas Strickland', 18)}}的其他基金
EVALUATING SILYMARIN IN CHRONIC HEPATITIS C
评估水飞蓟素治疗慢性丙型肝炎的效果
- 批准号:
6165632 - 财政年份:2000
- 资助金额:
$ 15.46万 - 项目类别:
相似海外基金
Immune Modulation During Acute Lyme Disease Infection as the Result of Aberrant Immunoglobulin Glycosylation
异常免疫球蛋白糖基化导致急性莱姆病感染期间的免疫调节
- 批准号:
10726417 - 财政年份:2023
- 资助金额:
$ 15.46万 - 项目类别:
Defining the host and pathogen determinants of peptidoglycan induced pathophysiology in Lyme disease
定义莱姆病肽聚糖诱导的病理生理学的宿主和病原体决定因素
- 批准号:
10566961 - 财政年份:2023
- 资助金额:
$ 15.46万 - 项目类别:
Auto-antibodies as predictive markers for Post treatment Lyme Disease Syndrome
自身抗体作为治疗后莱姆病综合征的预测标记
- 批准号:
10737996 - 财政年份:2023
- 资助金额:
$ 15.46万 - 项目类别:
Neuroimaging and blood markers in post treatment Lyme disease with persistent neurologic symptoms
具有持续神经系统症状的莱姆病治疗后的神经影像学和血液标记物
- 批准号:
10745421 - 财政年份:2023
- 资助金额:
$ 15.46万 - 项目类别:
ImmunoPET Probes for the Imaging of Lyme Disease
用于莱姆病成像的免疫PET探针
- 批准号:
10802275 - 财政年份:2023
- 资助金额:
$ 15.46万 - 项目类别:
Determinants of Post-Treatment Phenotypes in Lyme Disease
莱姆病治疗后表型的决定因素
- 批准号:
10738012 - 财政年份:2023
- 资助金额:
$ 15.46万 - 项目类别:
Elucidating the contributions of c-di-GMP and PlzA to tick- and mammalian host-adaptation in Lyme disease spirochetes
阐明 c-di-GMP 和 PlzA 对莱姆病螺旋体蜱和哺乳动物宿主适应的贡献
- 批准号:
10739945 - 财政年份:2023
- 资助金额:
$ 15.46万 - 项目类别:
The natural release of unusual peptidoglycan fragments drives persistent Lyme disease symptoms in susceptible hosts
异常肽聚糖片段的自然释放导致易感宿主持续出现莱姆病症状
- 批准号:
10736544 - 财政年份:2023
- 资助金额:
$ 15.46万 - 项目类别:
Unlocking serology’s secrets: harnessing novel immune biomarkers to predict Lyme disease progression and recovery
揭开血清学的秘密:利用新型免疫生物标志物来预测莱姆病的进展和恢复
- 批准号:
10737313 - 财政年份:2023
- 资助金额:
$ 15.46万 - 项目类别:














{{item.name}}会员




